Ledraxen

Enoxaparin Sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile injectable solution for subcutaneous, intravenous, and haemodialysis use. It is employed to prevent and treat venous thromboembolism, to provide anticoagulation during surgical procedures, and to manage acute coronary syndromes.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Ledraxen, a low molecular weight heparin, is indicated for several thrombo‑embolic conditions and peri‑operative anticoagulation.

- Deep vein thrombosis (DVT): prevents clot formation and propagation in at‑risk patients. - Pulmonary embolism (PE): reduces the risk of recurrent embolic events. - Surgical anticoagulation: lowers peri‑operative thrombotic complications. - Acute coronary syndrome (ACS): serves as an adjunct anticoagulant during acute management. - Haemodialysis anticoagulation: maintains circuit patency during renal replacement therapy.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects: - Injection site pain or bruising - Minor bleeding (e.g., gum, nosebleeds) - Nausea or mild gastrointestinal upset - Headache - Elevated liver enzymes - Transient rash at injection site

Serious or Rare Side Effects: - Major bleeding (intracranial, gastrointestinal) - Heparin‑induced thrombocytopenia (HIT) - Allergic or anaphylactic reactions - Spinal or epidural hematoma - Severe hypotension - Skin necrosis at injection sites

Careful assessment and monitoring are required before and during therapy.

- Renal impairment: adjust dose or monitor anti‑Xa activity. - Bleeding risk: evaluate history of hemorrhage before initiation. - Pregnancy: use only when potential benefit outweighs risk. - Surgery or invasive procedures: discontinue according to guideline‑based intervals. - Concomitant antiplatelet or anticoagulant therapy: monitor for additive bleeding. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants) – heightened bleeding risk. - Combination with systemic thrombolytics – excessive hemorrhage potential. - Spinal or epidural anesthesia/neuraxial procedures – risk of hematoma. - Presence of heparin‑induced thrombocytopenia antibodies – cross‑reactivity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may increase minor bleeding. - Antiplatelet agents (aspirin, clopidogrel) – monitor for additive bleeding. - Selective serotonin reuptake inhibitors (SSRIs) – possible increase in bleeding tendency.